Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Overview
Analysis
Risks
Rating
Chart
Analysts
Street
Sentiment
Earnings
Headlines
LLY
Eli Lilly and Company
$804.62
2045
Overview
Analysis
Risks
Rating
Chart
Analysts
Street
Sentiment
Earnings
Headlines
LLY Stock Rating Review
Login to display Eli Lilly and Company (LLY) recommendation from the last 90 days from financial news and social media.
LLY Total Score
Strengths
Earnings are forecast to grow
Investors confidence is positive
Outperform the market
Chart
878.45
755.91
762.66
458.37
LLY Risk Level
This Indicator assigning LLY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.
Risk Volatility
LLY has Low Risk Level
Click here to check what is your level of risk
LLY Analysts Opinion
LLY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Earnings increase YoY
Above analyst estimates
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Outperform the market
LLY Analysts opinion is positive and also has improved from the past 3 months
LLY Street Consensus
Analysts perspectives on the stock desirability, trend direction, and growth potential.
Opinion
Score
Score
LLY Street view is extremely ish and have positive views on the near-term outlook
LLY Performance Sentiment
events present
events present
Bullish
Neutral
Bearish
Very Bearish
LLY Earnings
The TTM reflects 12-month period, providing review of LLY financial performance.
LLY Financial Health
The company financial health has significantly improved over the past year, reflecting strong market demand and effective business strategies. Enhanced profitability and efficient cost management have contributed to this positive trend. The transition from a loss to profitability indicates a solid turnaround in operations, supported by better financial management.
Financial Score
NVO
Novo Nordisk A/S Com
126.73
-0.84%
AZN
Astrazeneca
78.13
-0.50%
ZTS
Zoetis
179.89
-0.42%
NVS
Novartis AG
110.28
+0.30%
MRK
Merck Company
125.26
-0.48%
Explore our LLY Stock insights
- In-Depth Market Analysis and Trends
- Expert Insights on Market Dynamics
- Tailored LLY Stock Strategies
- Effective Risk Management
FIND US ON
Receive our LLY Daily Alerts
Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses.
Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
